APRISO
Active substance: mesalamine
CAPSULE, EXTENDED RELEASE · MESALAMINE 375 mg/1
United StatesActive
Marketing holder: Salix Pharmaceuticals, Inc.
Verified 2026-10-09 · openFDA NDC
- Source: openFDA NDC
Composition
- MESALAMINE · 375 mg/1
Registration
- Registration number
- 65649-103
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- ORAL
Sources
- product · openFDA NDC · 65649-103 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 65649-103 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 65649-103 · Verified 2026-10-09 · open in source